This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback